The Consortium of Independent Immunology Clinics is grateful for the support from our corporate partners who are committed to improving the lives of patients around the world. It is the generosity of these sponsors that allows the CIIC and its members the opportunity to continue to participate in research that benefits PIDD patients.
ADMA Biologics is an end-to-end commercial biopharmaceutical company committed to manufacturing, marketing, and developing specialty plasma-derived products for the prevention and treatment of infectious diseases in the immune compromised and other patients at risk for infection.
With three FDA-licensed approved products, including ASCENIV™ (Immune Globulin Intravenous, Human – slra), BIVIGAM® (Immune Globulin Intravenous, Human), and NABI-HB® (Hepatitis B Immune Globulin, Human), ADMA’s mission is to continue to successfully develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases and management of immune compromised patient populations.
Amgen is one of the world’s leading biotechnology companies. Amgen is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
BioCryst is a biotech company committed to discovering novel, oral, small-molecule medicines that treat rare diseases in which significant unmet needs exist. We’re dedicated to delivering extraordinary medicines that empower patients to live ordinary lives. In December 2020, the FDA approved ORLADEYO® (berotralstat). Visit our booth to learn more.
A world leader in the field of in vitro diagnostics for 60 years, bioMérieux provides diagnostic solutions (systems, reagents, software) that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s products are mainly used for diagnosing infectious diseases.
Blueprint Medicines is a global precision therapy company that aims to invent transformative treatments for people with systemic mastocytosis, mast cell disorders and other difficult-to-treat diseases.
Since 2011, we have leveraged our research platform and world-class drug design capabilities to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering our approved medicines to patients in the United States and Europe, and we are globally advancing multiple programs.
CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We meet patients’ needs using the latest technologies to develop and deliver innovative biotherapies that are used to treat serious and rare conditions, such as coagulation disorders, primary immune deficiencies, hereditary angioedema and respiratory disease.
CuraScript SD provides integrated delivery solutions for the safe & efficient distribution of specialty pharmaceuticals & associated medical supplies. We’ve been caring for those who care for more than a quarter of a century by supplying biologics, branded drugs, generics, vaccines, infused medications and ancillary supportive care products to a wide range of medical providers.
Grifols is a global healthcare company that since its founding in Barcelona in 1909 has enhanced the health and well-being of people around the world.
We produce essential plasma medicines for patients to treat chronic, rare and, at times, life-threatening conditions. The company provides a comprehensive portfolio of solutions in transfusion medicine and also offers hospitals, pharmacies and healthcare professionals information and services that deliver efficient, expert medical care.
Grifols, with nearly 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety, and ethical leadership in the industry. For more information, please visit http://grifols.com.
Health iPASS is a patient engagement and payment solution that streamlines the payment process for healthcare providers and their patients. Our platform offers a variety of payment options, including credit card, debit card, HSA/FSA card, and mobile wallet (Apple Pay and Google Pay), making it the easiest way for patients to pay.
Health iPASS also provides patient engagement features such as scheduling, appointment reminders, express check-in, cost estimation, and post-visit surveys.
By choosing Health iPASS, healthcare providers can increase collections, and reduce administrative burden, while patients enjoy a hassle-free payment experience and greater engagement with their healthcare providers.
Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com, follow us @HorizonNews on Twitter, like us on Facebook or explore career opportunities on LinkedIn.
Intellia Therapeutics was formed in 2014 to lead the industry in one of the most promising new areas of therapeutic development: gene editing and repair using CRISPR-Cas9 technology. Intellia holds exclusive access to one of the most comprehensive intellectual property platforms available for the therapeutic use of CRISPR-Cas9. The company is advancing a broad pipeline toward clinical development, including ex vivo and in vivo approaches.
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis has developed three currently marketed medicines and has a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.
KalVista Pharmaceuticals, Inc. is focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista has developed a portfolio of novel, small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE). KalVista is developing sebetralstat as an oral on-demand therapy for acute HAE attacks in the Phase 3 KONFIDENT clinical trial, and KVD824 for prophylactic treatment of HAE in the Phase 2 KOMPLETE clinical trial. Additionally, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve treatment of HAE for patients.
Octapharma USA is a subsidiary of Octapharma AG, a global human protein products manufacturer. The company is dedicated to the research and manufacture of human proteins and has been committed to patient care and medical innovation for more than 30 years. Its core business is the development, production and sale of human proteins from human plasma and human cell-lines. Patients are treated with Octapharma products in the therapeutic areas of hematology, immunotherapy, and critical care. Octapharma USA is headquartered in Paramus, N.J. Octapharma operates three state-of-the-art production sites licensed by the U.S. Food and Drug Administration (FDA), providing a high level of production flexibility. For more information, please visit www.octapharmausa.com.
Pharming Healthcare, Inc. is a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs.
Regeneron is a leading biotechnology company that invents medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to multiple FDA-approved treatments, almost all of which were homegrown in our laboratories.
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discovering and delivering life-transforming treatments, and guided by our commitment to patients, our people, and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines.